Evaluation of Virtual Reality Headsets on Cancer Patients During Day Hospital Stay

Use of virtula reality headsets during treatment course on day hospitalized cancer patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ICAP

Avignon, 84918, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

cancer patients
chemotherapy treatment

Exclusion criteria

Treatment and study plan

Survey using a questionnaire

Other

virtual reality headset is added during treatment administration. Patient must complete a survey at the end of treatment administration and virtual headset use.

Primary outcomes

Rate of patients with nausea reduction compared with preview treatment administration

Time frame: From the first chemotherapy injection until the end of chemotherapy injection with the virtual reality headset (at the end of the third cycle; each cycle is 21 days) )

survey : improvement of nausea

Sponsors and collaborators

Lead sponsor

Institut Sainte Catherine

Other

Registry information

Official study title

Prospective Evaluation of Virtual Reality Headsets on Cancer Patients During Day Hospital Stay

Acronym: VIRTUEL

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Feb 7, 2025
Registry last updated: Feb 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed